BioCentury | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
BioCentury | Oct 12, 2018
Company News

Roche gets option to Ionis' antisense dry AMD candidate

Roche (SIX:ROG; OTCQX:RHHBY) will pay Ionis Pharmaceuticals Inc. (NASDAQ:IONS) $75 million up front for an option to develop and commercialize IONIS-FB-LRx, a ligand-conjugated antisense (LICA) oligonucleotide targeting complement factor B (CFB). The partners plan to...
BioCentury | Oct 10, 2018
Company News

Roche gets option to Ionis' antisense dry AMD candidate

Roche (SIX:ROG; OTCQX:RHHBY) will pay Ionis Pharmaceuticals Inc. (NASDAQ:IONS) $75 million up front for an option to develop and commercialize IONIS-FB-LRx, a ligand-conjugated antisense (LICA) oligonucleotide targeting complement factor B (CFB). The partners plan to...
BioCentury | Oct 12, 2017
Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
BioCentury | Aug 18, 2017
Company News

GSK declines option to Ionis' inotersen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined...
BioCentury | Aug 11, 2017
Company News

GSK declines option to Ionis' inotersen

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined its exclusive option to license inotersen ahead of regulatory submissions, which would have triggered a $45 million milestone payment to Ionis. The pharma also declined...
BioCentury | Mar 24, 2016
Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
Items per page:
1 - 7 of 7